Improved Chemotherapy for Small-Cell Undifferentiated Lung Cancer

Lawrence Einhorn, Mark O. Farber, Robert B. Livingston, Jeffrey A. Gottlieb

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Bleomycin sulfate, doxorubicin hydrochloride, cyclophosphamide, and vincristine sulfate combination chemotherapy was given to 29 patients with small-cell undifferentiated lung cancer. Only four of these patients had limited disease, and in these patients there was 100% complete remission; two of these four patients remain in complete remission at more than 52 and 60 weeks. Of the 25 patients with generalized disease, 18 (72%) had neoplasm regression (>50%), including two with complete remission (8%). The median duration of remission was 25 weeks. The median survival time from diagnosis was 39 weeks and that from initiation of therapy, 35 weeks. The drug regimen was well tolerated, and although substantial leukopenia was produced, there were only three patients in whom granulocytopenic infections developed. There was only one drug-related death.

Original languageEnglish
Pages (from-to)1225-1229
Number of pages5
JournalJournal of the American Medical Association
Volume235
Issue number12
DOIs
StatePublished - Mar 22 1976

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Bleomycin
Leukopenia
Vincristine
Combination Drug Therapy
Pharmaceutical Preparations
Doxorubicin
Cyclophosphamide
Survival
Infection
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Improved Chemotherapy for Small-Cell Undifferentiated Lung Cancer. / Einhorn, Lawrence; Farber, Mark O.; Livingston, Robert B.; Gottlieb, Jeffrey A.

In: Journal of the American Medical Association, Vol. 235, No. 12, 22.03.1976, p. 1225-1229.

Research output: Contribution to journalArticle

Einhorn, Lawrence ; Farber, Mark O. ; Livingston, Robert B. ; Gottlieb, Jeffrey A. / Improved Chemotherapy for Small-Cell Undifferentiated Lung Cancer. In: Journal of the American Medical Association. 1976 ; Vol. 235, No. 12. pp. 1225-1229.
@article{61c53db43f104447b8e23e257bd96ef0,
title = "Improved Chemotherapy for Small-Cell Undifferentiated Lung Cancer",
abstract = "Bleomycin sulfate, doxorubicin hydrochloride, cyclophosphamide, and vincristine sulfate combination chemotherapy was given to 29 patients with small-cell undifferentiated lung cancer. Only four of these patients had limited disease, and in these patients there was 100{\%} complete remission; two of these four patients remain in complete remission at more than 52 and 60 weeks. Of the 25 patients with generalized disease, 18 (72{\%}) had neoplasm regression (>50{\%}), including two with complete remission (8{\%}). The median duration of remission was 25 weeks. The median survival time from diagnosis was 39 weeks and that from initiation of therapy, 35 weeks. The drug regimen was well tolerated, and although substantial leukopenia was produced, there were only three patients in whom granulocytopenic infections developed. There was only one drug-related death.",
author = "Lawrence Einhorn and Farber, {Mark O.} and Livingston, {Robert B.} and Gottlieb, {Jeffrey A.}",
year = "1976",
month = "3",
day = "22",
doi = "10.1001/jama.1976.03260380019019",
language = "English",
volume = "235",
pages = "1225--1229",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Improved Chemotherapy for Small-Cell Undifferentiated Lung Cancer

AU - Einhorn, Lawrence

AU - Farber, Mark O.

AU - Livingston, Robert B.

AU - Gottlieb, Jeffrey A.

PY - 1976/3/22

Y1 - 1976/3/22

N2 - Bleomycin sulfate, doxorubicin hydrochloride, cyclophosphamide, and vincristine sulfate combination chemotherapy was given to 29 patients with small-cell undifferentiated lung cancer. Only four of these patients had limited disease, and in these patients there was 100% complete remission; two of these four patients remain in complete remission at more than 52 and 60 weeks. Of the 25 patients with generalized disease, 18 (72%) had neoplasm regression (>50%), including two with complete remission (8%). The median duration of remission was 25 weeks. The median survival time from diagnosis was 39 weeks and that from initiation of therapy, 35 weeks. The drug regimen was well tolerated, and although substantial leukopenia was produced, there were only three patients in whom granulocytopenic infections developed. There was only one drug-related death.

AB - Bleomycin sulfate, doxorubicin hydrochloride, cyclophosphamide, and vincristine sulfate combination chemotherapy was given to 29 patients with small-cell undifferentiated lung cancer. Only four of these patients had limited disease, and in these patients there was 100% complete remission; two of these four patients remain in complete remission at more than 52 and 60 weeks. Of the 25 patients with generalized disease, 18 (72%) had neoplasm regression (>50%), including two with complete remission (8%). The median duration of remission was 25 weeks. The median survival time from diagnosis was 39 weeks and that from initiation of therapy, 35 weeks. The drug regimen was well tolerated, and although substantial leukopenia was produced, there were only three patients in whom granulocytopenic infections developed. There was only one drug-related death.

UR - http://www.scopus.com/inward/record.url?scp=0017313201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017313201&partnerID=8YFLogxK

U2 - 10.1001/jama.1976.03260380019019

DO - 10.1001/jama.1976.03260380019019

M3 - Article

VL - 235

SP - 1225

EP - 1229

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 12

ER -